X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa-2, which exhibits mesenchymal and amoeboid motility

Cancer Science

Volumn 102, Issue 4, 2011, Pages 792-798

  Fujita, Mayumi ^a   Otsuka, Yoshimi ^a   Yamada, Shigeru ^a   Iwakawa, Mayumi ^a   Imai, Takashi ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; GELATINASE A; ILOMASTAT; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; RHO KINASE INHIBITOR;

AMOEBOID MESENCHYMAL TRANSITION; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER RADIOTHERAPY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CELL TRANSFORMATION; GAMMA RADIATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; UPREGULATION; X IRRADIATION;

AMOEBA; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; DIPEPTIDES; HUMANS; MATRIX METALLOPROTEINASES; MESODERM; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; X-RAYS;

EID: 79952768247     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01852.x     Document Type: Article

References (40)

1. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009; 6: 412-22.
2. Lau WY, Lai ECH. Development and controversies of adjuvant therapy for pancreatic cancer. Hepatobiliary Pancreat Dis Int 2008; 7: 121-5.
3. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003; 2: 1-7.
4. Ruano-Ravina A, Ortega RA, Guedea F. Intraoperative radiotherapy in pancreatic cancer: a systemic review. Radiother Oncol 2008; 87: 318-25.
5. Qian LW, Mizumoto K, Urashima T et al. Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor; CGS27023. Clin Cancer Res 2002; 8: 1223-7.
6. Ogata T, Teshima T, Kagawa K et al. Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res 2005; 65: 113-20.
7. Wolf K, Mazo I, Leung H et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003; 160: 267-77.
8. Sanz-Morero V, Gadea G, Ahn J et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008; 135: 510-23.
9. Pinner S, Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 2008; 10: 127-37.
10. Yamazaki D, Kurisu S, Takenawa T. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. Oncogene 2009; 28: 1570-83.
11. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009; 28: 65-76.
12. Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol 2010; 188: 11-9.
13. Mishima T, Naotsuka M, Horita Y, Sato M, Ohashi K, Mizuno K. LIM-kinase is critical for the mesenchymal-to-amoeboid cell morphological transition in 3D matrices. Biochem Biophys Res Commun 2010; 392: 577-81.
14. Matsumoto Y, Iwakawa M, Furusawa Y et al. Gene expression analysis in human malignant melanoma cell lines exposed to carbon beams. Int J Radiat Biol 2008; 84: 299-314.
15. Park JH, Han HJ. Caveolin-1 plays important role in EGF-induced migration and proliferation of mouse embryonic stem cells: involvement of PI3K/Akt and ERK. Am J Physiol Cell Physiol 2009; 297: C935-44.
16. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int 2004; 11: 36-42.
17. Kaneshiro ES, Wyder MA, Wu YP, Cushion MT. Reliability of calcein acetoxy methyl ester and ethidium homodimer or propidium iodide for viability assessment of microbes. J Microbiol Methods 1993; 17: 1-16.
18. Albini AY, Iwamoto H, Kleinman KG et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45.
19. Imadome K, Iwakawa M, Nojiri K et al. Upregulation of stress-response genes with cell cycle arrest induced by carbon ion irradiation in multiple murine tumors models. Cancer Biol Ther 2008; 7: 208-17.
20. Sato H, Takino T, Miyamori H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 2005; 96: 212-7.
21. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007; 26: 587-96.
22. Akino Y, Teshima T, Kihara A et al. Carbon-ion beam irradiation effectively suppresses migration and invasion of human non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 2009; 75: 475-81.
23. Goetze K, Scholz M, Taucher-Scholz G, Mueller-Klieser W. The impact of conventional and heavy ion irradiation on tumor cell migration in vitro. Int J Radiat Biol 2007; 83: 889-96.
24. Salhia B, Rutten F, Nakada M et al. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res 2005; 65: 8792-800.
25. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009; 69: 8742-51.
26. Deng L, Li G, Li R, Liu Q, He Q, Zhang J. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther 2010; 9: 875-84.
27. Micuda S, Rösel D, Ryska A, Brabek J. ROCK inhibitors as emerging therapeutic candidates for sarcomas. Curr Cancer Drug Targets 2010; 10: 127-34.
28. Sun XZ, Li ZF, Liu Y, Fang P, Li MX. Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells. Clin Exp Pharmacol Physiol 2010; 37: 362-7.
29. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 2006; 16: 1515-23.
30. Xue F, Takahara T, Yata Y et al. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 2008; 38: 810-7.
31. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999; 274: 29130-7.
32. Pan MR, Hung WC. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 2002; 277: 32775-80.
33. Zhao W, Goswami PC, Robbins ME. Radiation-induced up-regulation of Mmp2 involves increased mRNA stability, redox modulation, and MAPK activation. Radiat Res 2004; 161: 418-29.
34. Park CM, Park MJ, Kwak HJ et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006; 66: 8511-9.
35. Jones L, Ghaneh P, Humphreys M, Neoptolemos JP. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci 1999; 880: 288-307.
36. Koshiba T, Hosotani R, Wada M et al. Involvement of MMP2 activity in invasion and metastases of pancreatic cancer. Cancer 1998; 82: 642-50.
37. Bramhall SR, Stamp GWH, Dunn J, Lemoine NR, Neoptolemos JP. Expression on collagenease (MMP2), stromelysin (MMP3), and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996; 73: 972-8.
38. Kruger A, Soeltl R, Sopov I et al. Hydroxamate-type matrix metalloproteinase inhibitor batismastat promotes liver metastasis. Cancer Res 2001; 61: 1272-5.
39. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-55.
40. Moore MJ, Hamm P, Eisenberg P, Dagenais M, Hagan K, Fields A. A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19: 240a.